FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jacob Lalezari

Research Profile

Disorders

Living Beings

Chemicals & Drugs

Procedures

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Sherene Min; Stephen Piscitelli; Louis Sloan; Ivy Song; Richard Stroder; Mark Underwood; Shuguang Chen; Edwin DeJesus; Tamio Fujiwara; Trevor Hawkins; Lewis McCurdy; Jacob P Lalezari
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
Jacob P Lalezari; Michael Saag; Charles Walworth; Peter Larson
An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).
Frances Priddy; Deborah Brown; James Kublin; Kathleen Monahan; David P Wright; Jacob P Lalezari; Steven Santiago; Michael Marmor; Michelle Lally; Richard M Novak; Stephen J Brown; Priya Kulkarni; Sheri A Dubey; Lisa S Kierstead; Danilo R Casimiro; Robin Mogg; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Michael N Robertson; Devan V Mehrotra; Erin Quirk
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jacob Lalezari (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Sherene Min; Stephen Piscitelli; Louis Sloan; Ivy Song; Richard Stroder; Mark Underwood; Shuguang Chen; Edwin DeJesus; Tamio Fujiwara; Trevor Hawkins; Lewis McCurdy; Jacob P Lalezari
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
AIDS (London, England) 2011;25(14):1737-45.
2008: Jacob P Lalezari; Michael Saag; Charles Walworth; Peter Larson
An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).
AIDS research and human retroviruses 2008;24(6):805-13.
2008: Frances Priddy; Deborah Brown; James Kublin; Kathleen Monahan; David P Wright; Jacob P Lalezari; Steven Santiago; Michael Marmor; Michelle Lally; Richard M Novak; Stephen J Brown; Priya Kulkarni; Sheri A Dubey; Lisa S Kierstead; Danilo R Casimiro; Robin Mogg; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Michael N Robertson; Devan V Mehrotra; Erin Quirk
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(11):1769-81.
2008: Raxit J Jariwalla; Jacob P Lalezari; Diane Cenko; Sam E Mansour; Abha Kumar; Bhakti Gangapurkar; Daniel Nakamura
Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection.
Journal of alternative and complementary medicine (New York, N.Y.) 2008;14(2):139-46.
2008: Jacob P Lalezari; Gopal K Yadavalli; Michael Para; Gary Richmond; Edwin DeJesus; Stephen J Brown; Wendy Cai; Cecil Chen; John Zhong; Lu Anne Novello; Michael M Lederman; G. SUBRAMANIAN
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
The Journal of infectious diseases 2008;197(5):721-7.
2008: Richard Davey; Peter E Pertel; Alice Benson; Delanie J Cassell; Brian G Gazzard; Mark Holodniy; Jacob P Lalezari; Yves Levy; Ronald T Mitsuyasu; Frank J Palella; Richard B Pollard; Prabhu Rajagopalan; Michael S Saag; Robert A Salata; Beverly E Sha; Shurjeel Choudhri
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2008;28(2):89-100.
2007: Jacques Reynes; Keikawus Arastéh; Bonaventura Clotet; Calvin Cohen; David A Cooper; Jean-François Delfraissy; Joseph J Eron; Keith Henry; Christine Katlama; Daniel R Kuritzkes; Jacob P Lalezari; Joep Lange; Adriano Lazzarin; Julio S G Montaner; Mark Nelson; Mary O' Hearn; Hans-Jürgen Stellbrink; Benoit Trottier; Sharon L Walmsley; Neil E Buss; Ralph DeMasi; Jain Chung; Lucille Donatacci; Denise Guimaraes; Lucy Rowell; Adeline Valentine; Martin Wilkinson; Miklos Salgo
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
AIDS patient care and STDs 2007;21(8):533-43.
2007: Esper Kallas; Pedro Cahn; Beatriz Grinsztejn; Richard Haubrich; Jacob P Lalezari; Anthony Mills; Gilles Pialoux; Timothy Wilkin; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Lorant Leopold; Roberta Trefiglio; Brian Woodfall
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet 2007;370(9581):29-38.
2007: Jacob P Lalezari; Douglas J Ward; Susan A Tomkins; Harmony P Garges
Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
The Journal of antimicrobial chemotherapy 2007;60(1):170-4.
2006: Guy de Bruyn; Mauricio Vargas-Cortez; Terri Warren; Stephen K Tyring; Kenneth H Fife; Jacob P Lalezari; Rebecca C Brady; Mohsen Shahmanesh; George Kinghorn; Karl R Beutner; Rajul Patel; Margaret A Drehobl; Patrick Horner; Terrance O Kurtz; Sharon McDermott; Anna Wald; Lawrence Corey
A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.
Vaccine 2006;24(7):914-20.
2005: Mark Nelson; Keikawus Arastéh; Bonaventura Clotet; David A Cooper; Keith Henry; Christine Katlama; Jacob P Lalezari; Adriano Lazzarin; Julio S G Montaner; Mary E O'Hearn; Peter J Piliero; Jacques Reynes; Benoit Trottier; Sharon L Walmsley; Calvin Cohen; Joseph J Eron; Daniel R Kuritzkes; Joep Lange; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Neil E Buss; Lucille Donatacci; Cynthia Wat; Lynn Smiley; Martin Wilkinson; Adeline Valentine; Denise Guimaraes; Ralph DeMasi; Jain Chung; Miklos Salgo
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):404-12.
2005: Jacob P Lalezari; Melanie Thompson; Priny Kumar; Peter J Piliero; Richard Davey; Kristine Patterson; Anne Shachoy-Clark; Kimberly K Adkison; James Demarest; Yu Lou; M Michelle Berrey; Stephen C Piscitelli
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
AIDS (London, England) 2005;19(14):1443-8.
2005: Eileen Glutzer; Jacob P Lalezari
Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impact.
The Journal of the Association of Nurses in AIDS Care : JANAC 2005;16(5):26-34.
2005: Jacob P Lalezari; Nicholaos C Bellos; Kunthavi Sathasivam; Gary J Richmond; Calvin J Cohen; Robert A Myers; David H Henry; Claire Raskino; Tom Melby; Hugh Murchison; Ying Zhang; Rebecca Spence; Michael L Greenberg; Ralph DeMasi; G Diego Miralles
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
The Journal of infectious diseases 2005;191(7):1155-63.
2004: Xiaoping Zhang; Jacob P Lalezari; andrew badley; Albert Dorr; Stanley J Kolis; Tosca Kinchelow; Indravadan H Patel
Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients.
Clinical pharmacology and therapeutics 2004;75(6):558-68.
2004: David A Wheeler; Jacob P Lalezari; J. Michael Kilby; Joseph Wheat; John Delehanty; Ralph DeMasi; Indravadan H Patel; Miklos Salgo
Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2004;30(2):183-90.
2004: Jacob P Lalezari; Andrew D Luber
Enfuvirtide.
Drugs of today (Barcelona, Spain : 1998) 2004;40(3):259-69.
2003: Jacob P Lalezari; Indravadan H Patel; Xiaoping Zhang; Albert Dorr; Nina Hawker; Zikia Siddique; Stanley J Kolis; Tosca Kinchelow
Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2003;28(2):217-22.
2003: Jacob P Lalezari; Edwin DeJesus; Donald W Northfelt; Gary J Richmond; Peter Wolfe; Richard Haubrich; David Henry; William G Powderly; Stephen Becker; Melanie Thompson; Fred Valentine; David Wright; Margrit Carlson; Sharon A Riddler; Frances F Haas; Ralph DeMasi; Prakash Sista; Miklos Salgo; John Delehanty
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Antiviral therapy 2003;8(4):279-87.
2003: Jacob P Lalezari; Keith Henry; Mary E O'Hearn; Julio S G Montaner; Peter J Piliero; Benoit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
The New England journal of medicine 2003;348(22):2175-85.
2003: Jacob P Lalezari; Joseph J Eron; Margrit Carlson; Calvin Cohen; Edwin DeJesus; Roberto C Arduino; Joel E Gallant; Paul A Volberding; Robert L Murphy; Fred Valentine; Emily L Nelson; Prakash Sista; Alex Dusek; J. Michael Kilby
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
AIDS (London, England) 2003;17(5):691-8.
2003: Jacob P Lalezari
Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
The AIDS reader 2003;13(3 Suppl):S9-13.
2002: Jacob P Lalezari; Judith A Aberg; Laurene H Wang; Mary Beth Wire; Richard C Miner; Wendy Snowden; Christine L Talarico; Shuching Shaw; Mark A Jacobson; W Lawrence Drew
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.
Antimicrobial agents and chemotherapy 2002;46(9):2969-76.
2002: Jacob P Lalezari; Janette Lindley; Sharon Walmsley; Baruch Kuppermann; Martin Fisher; Dorothy N Friedberg; Richard Lalonde; Sophie Matheron; Leopoldo Nieto; Francesca J Torriani; Rod Van Syoc; Mary Ann Sutton; William C Buhles; Mary Jean Stempien
A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
Journal of acquired immune deficiency syndromes (1999) 2002;30(4):392-400.
2002: J. Michael Kilby; Jacob P Lalezari; Joseph J Eron; Margrit Carlson; Calvin Cohen; Roberto C Arduino; Jeffrey C Goodgame; Joel E Gallant; Paul A Volberding; Robert L Murphy; Fred Valentine; Michael S Saag; Emily L Nelson; Prakash Sista; Alex Dusek
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
AIDS research and human retroviruses 2002;18(10):685-93.
2002: Jacob P Lalezari; Dorothy N Friedberg; Jack Bissett; Michael F Giordano; W David Hardy; W Lawrence Drew; Larry D Hubbard; William C Buhles; Mary Jean Stempien; Panos Georgiou; Donald T Jung; Charles A Robinson
High dose oral ganciclovir treatment for cytomegalovirus retinitis.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2002;24(1-2):67-77.
2001: Krishna Komanduri; J Feinberg; R K Hutchins; R D Frame; DK Schmidt; M N Viswanathan; Jacob P Lalezari; Joseph M McCune
Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.
The Journal of infectious diseases 2001;183(8):1285-9.
2000: Jacob P Lalezari; J A Beal; Peter Ruane; C J Cohen; E L Jacobson; DJ Sundin; W P Leong; S P Raffanti; D A Wheeler; R D Anderson; P Keiser; S R Schrader; J C Goodgame; Corklin R Steinhart; Robert L Murphy; M J Wolin; Kendall A Smith
Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
HIV clinical trials 2000;1(3):1-15.
1999: W Lawrence Drew; Jacob P Lalezari
Cytomegalovirus: disease syndromes and treatment.
Current clinical topics in infectious diseases 1999;19():16-29.
1998: Julie M Cherrington; Michael D Fuller; PD Lamy; Richard C Miner; Jacob P Lalezari; S Nuessle; W Lawrence Drew
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.
The Journal of infectious diseases 1998;178(6):1821-5.
1998: John W Gnann; C S Crumpacker; Jacob P Lalezari; J A Smith; Stephen Tyring; Kenneth Baum; M J Borucki; W P Joseph; Gregory J Mertz; Roy T Steigbigel; Gretchen A Cloud; Seng-Jaw Soong; L C Sherrill; D A DeHertogh; Richard J Whitley
Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group.
Antimicrobial agents and chemotherapy 1998;42(5):1139-45.
1998: Jacob P Lalezari; Gary N Holland; F Kramer; G F McKinley; C A Kemper; D V Ives; R Nelson; W David Hardy; Baruch D Kuppermann; Donald W Northfelt; M Youle; M Johnson; Richard Alan Lewis; David V Weinberg; G L Simon; Richard A Wolitz; A E Ruby; R J Stagg; HS Jaffe
Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;17(4):339-44.
1997: Steven G Deeks; A Collier; Jacob P Lalezari; A Pavia; D Rodrigue; W Lawrence Drew; J Toole; HS Jaffe; Andrew S Mulato; PD Lamy; W Li; Julie M Cherrington; Nicholas S Hellmann; J Kahn
The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
The Journal of infectious diseases 1997;176(6):1517-23.
1997: David Chernoff; Richard C Miner; B S Hoo; Lu-Ping Shen; R J Kelso; D Jekic-McMullen; Jacob P Lalezari; Sunwen Chou; W Lawrence Drew; Janice A Kolberg
Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay.
Journal of clinical microbiology 1997;35(11):2740-4.
1997: Jacob P Lalezari; T Schacker; J Feinberg; J Gathe; S Lee; T Cheung; F Kramer; H Kessler; L Corey; W Lawrence Drew; J Boggs; B McGuire; HS Jaffe; S Safrin
A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.
The Journal of infectious diseases 1997;176(4):892-8.
1997: Sunwen Chou; Gail I Marousek; S Guentzel; S E Follansbee; M E Poscher; Jacob P Lalezari; Richard C Miner; W Lawrence Drew
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
The Journal of infectious diseases 1997;176(3):786-9.
1997: Jacob P Lalezari
New treatment options for CMV retinitis in AIDS.
Advance for nurse practitioners 1997;5(4):45-9, 83.
1997: Jacob P Lalezari; R J Stagg; Baruch D Kuppermann; Gary N Holland; F Kramer; D V Ives; M Youle; M R Robinson; W Lawrence Drew; HS Jaffe
Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial.
Annals of internal medicine 1997;126(4):257-63.
1997: Jacob P Lalezari; Baruch D Kuppermann
Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;14 Suppl 1():S27-31.
1997: Jacob P Lalezari
Cidofovir: a new therapy for cytomegalovirus retinitis.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;14 Suppl 1():S22-6.
1996: Stephen A Spector; G F McKinley; Jacob P Lalezari; T Samo; R Andruczk; S Follansbee; P D Sparti; Diane V Havlir; G Simpson; W Buhles; R Wong; M Stempien
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.
The New England journal of medicine 1996;334(23):1491-7.
1996: Julie M Cherrington; Richard C Miner; M J Hitchcock; Jacob P Lalezari; W Lawrence Drew
Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug.
The Journal of infectious diseases 1996;173(4):987-92.
1996: K Peter; Jacob P Lalezari; JG Gambertoglio
Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method.
Journal of pharmaceutical and biomedical analysis 1996;14(4):491-9.
1996: Jacob P Lalezari; R J Stagg; HS Jaffe; M J Hitchcock; W Lawrence Drew
A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC).
Advances in experimental medicine and biology 1996;394():105-15.
1995: G J Yuen; George L Drusano; C Fletcher; E Capparelli; James D Connor; Jacob P Lalezari; L Drew; S Follansbee; D Busch; M Jacobson
Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.
Antimicrobial agents and chemotherapy 1995;39(10):2350-2.
1995: W Lawrence Drew; D Ives; Jacob P Lalezari; C Crumpacker; S E Follansbee; Stephen A Spector; Constance A Benson; Dorothy N Friedberg; L Hubbard; M J Stempien
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group.
The New England journal of medicine 1995;333(10):615-20.
1995: Stephen A Spector; D F Busch; S Follansbee; K Squires; Jacob P Lalezari; Mark A Jacobson; James D Connor; D Jung; A Shadman; B Mastre
Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group.
The Journal of infectious diseases 1995;171(6):1431-7.
1995: Kenneth C Cundy; Brent G Petty; J Flaherty; P E Fisher; Michael A Polis; M Wachsman; Paul S Lietman; Jacob P Lalezari; M J Hitchcock; HS Jaffe
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 1995;39(6):1247-52.
1995: Jacob P Lalezari; W Lawrence Drew; E Glutzer; C James; D Miner; J Flaherty; P E Fisher; Kenneth C Cundy; J Hannigan; J C Martin
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.
The Journal of infectious diseases 1995;171(4):788-96.
1995: W Lawrence Drew; R Anderson; W Lang; Richard C Miner; G Davis; Jacob P Lalezari
Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;8(3):289-91.
1994: Jacob P Lalezari; W Lawrence Drew; E Glutzer; D Miner; S Safrin; W F Owen; J M Davidson; P E Fisher; HS Jaffe
Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.
The Journal of infectious diseases 1994;170(3):570-2.
1993: Margaret A Fischl; R M Olson; S E Follansbee; Jacob P Lalezari; D H Henry; P T Frame; S C Remick; M P Salgo; A H Lin; C Nauss-Karol; J Lieberman; W Soo
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
Annals of internal medicine 1993;118(10):762-9.